PARIS, March 20, 2024 /PRNewswire/ — Cure51, a techbio company seeking to unlock the biological mechanisms responsible for exceptional survivors among cancer patients, today announced that it has successfully raised €15 million in a seed funding round led by Sofinnova Partners. Other…